BMPEA (also known as β-methylphenylethylamine, R-beta methylphenylethylamine, beta-methylphenethylamine and others) is an unapproved amphetamine-like substance that has been appearing in some dietary supplement products. BMPEA was first made in the 1930s as a possible replacement to amphetamine (a central nervous system stimulant), although it never became a drug because no studies were performed on its safety in humans. More recent studies, however, have shown that BMPEA can raise blood pressure and increase the risk of a cardiovascular event.

In 2017 the Food and Drug Administration (FDA) tested 21 supplement products with the ingredient Acacia rigidula listed on the label and found that 9 of the 21 products contained BMPEA, which is not derived from the plant Acacia rigidula. Some dietary supplement products actually list BMPEA (often using one of the terms listed above) on their labels.

FDA has issued a warning stating, “…BMPEA does not meet the statutory definition of a dietary ingredient.” Therefore, dietary supplement products with BMPEA are misbranded and cannot be sold as dietary supplements. However, BMPEA continues to be found as an ingredient in dietary supplement products, including ones with “Acacia rigidula” on their labels.

The World Anti-Doping Agency has banned BMPEA, and BMPEA is also is on the OPSS list of DoD-prohibited ingredients.

 

Updated 13 July 2020

References

Brown, D. H., Hansson, R., Oosthuizen, F., & Sumner, N. (2015). β‐methylphenylethylamines: Common fragmentation pathways with amphetamines in electrospray ionization collision‐induced dissociation. Drug Testing and Analysis, 8(3-4), 344–350. doi:10.1002/dta.1816

Chołbiński, P., Wicka, M., Kowalczyk, K., Jarek, A., Kaliszewski, P., Pokrywka, A., . . . Kwiatkowska, D. (2014). Detection of β-methylphenethylamine, a novel doping substance, by means of UPLC/MS/MS. Analytical and Bioanalytical Chemistry, 406(15), 3681–3688. doi:10.1007/s00216-014-7728-5

Cohen, P. A., Bloszies, C., Yee, C., & Gerona, R. (2016). An amphetamine isomer whose efficacy and safety in humans has never been studied, β-methylphenylethylamine (BMPEA), is found in multiple dietary supplements. Drug Testing and Analysis, 8(3-4), 328–333. doi:10.1002/dta.1793

Cohen, P. A., Avula, B., Venhuis, B., Travis, J. C., Wang, Y.-H., & Khan, I. A. (2017). Pharmaceutical doses of the banned stimulant oxilofrine found in dietary supplements sold in the USA. Drug Testing and Analysis, 9(1), 135–142. doi:10.1002/dta.1976

Cohen, P. A., Travis, J. C., Keizers, P. H. J., Deuster, P., & Venhuis, B. J. (2017). Four experimental stimulants found in sports and weight loss supplements: 2-amino-6-methylheptane (octodrine), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylamylamine (1,3-DMAA) and 1,3-dimethylbutylamine (1,3-DMBA). Clinical Toxicology, 56(6), 421–426. doi:10.1080/15563650.2017.1398328

Cohen, P. A., Wen, A., & Gerona, R. (2018). Prohibited stimulants in dietary supplements after enforcement action by the U.S. Food and Drug Administration. JAMA Internal Medicine, 178(12), 1721–1723. doi:10.1001/jamainternmed.2018.4846

Eichner, S., Maguire, M., Shea, L. A., & Fete, M. G. (2016). Banned and discouraged-use ingredients found in weight loss supplements. Journal of the American Pharmacists Association, 56(5), 538–543. doi:10.1016/j.japh.2016.03.013

National Center for Biotechnology Information. PubChem Database: 2-Phenylpropylamine, CID=11398.   Retrieved 29 May 2019 from https://pubchem.ncbi.nlm.nih.gov/compound/2-Phenylpropylamine

Pawar, R. S., Grundel, E., Fardin-Kia, A. R., & Rader, J. I. (2014). Determination of selected biogenic amines in Acacia rigidula plant materials and dietary supplements using LC–MS/MS methods. Journal of Pharmaceutical and Biomedical Analysis, 88, 457–466. doi:10.1016/j.jpba.2013.09.012

Rasmussen, N., & Keizers, P. H. J. (2016). History full circle: ‘Novel’ sympathomimetics in supplements. Drug Testing and Analysis, 8(3-4), 283–286. doi:10.1002/dta.1852

Rickli, A., Hoener, M. C., & Liechti, M. E. (2019). Pharmacological profiles of compounds in preworkout supplements (“boosters”). European Journal of Pharmacology, 859, Article 172515. doi:10.1016/j.ejphar.2019.172515

Schindler, C. W., Thorndike, E. B., Rice, K. C., Partilla, J. S., & Baumann, M. H. (2019). The supplement adulterant β-methylphenethylamine increases blood pressure by acting at peripheral norepinephrine transporters. Journal of Pharmacology and Experimental Therapeutics, 369(3), 328–336. doi:10.1124/jpet.118.255976

U.S. Food & Drug Administration. (2017). BMPEA in dietary supplements. Retrieved 1 May 2019 from https://www.fda.gov/food/dietary-supplement-products-ingredients/bmpea-dietary-supplements

Yun, J., Kwon, K., Choi, J., & Jo, C.-H. (2017). Monitoring of the amphetamine-like substances in dietary supplements by LC-PDA and LC–MS/MS. Food Science and Biotechnology, 26(5), 1185–1190. doi:10.1007/s10068-017-0176-1

Zhao, J., Wang, M., Avula, B., & Khan, I. A. (2018). Detection and quantification of phenethylamines in sports dietary supplements by NMR approach. Journal of Pharmaceutical and Biomedical Analysis, 151, 347–355. doi:10.1016/j.jpba.2018.01.025